Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial

Citation
Pellicori P, Ofstad AP, Fitchett D, et al. Eur Heart J 2019;40(Suppl 1):P2629.